Domestic pharmaceutical companies are accumulating in the field of anti-tumor drugs, and good news comes out frequently

 New oncology drugs that are continuously approved for marketing have brought many very important clinical advances.
According to data, it is predicted that nearly 100 new active substances in oncology will be launched globally from 2021 to 2025, a growth rate of about 50% compared to the past five years
.
In China, pharmaceutical companies have also accumulated a lot of oncology drug innovation and R&D capabilities, and are in a period of rapid growth
.
Recently, there have been good news in the field of anti-tumor drugs
.
For example, on November 8, Hengrui Medicine issued an announcement stating that two anti-tumor drugs with a research and development investment of over 640 million yuan were approved for clinical trials
.
The two drugs are Apatinib mesylate tablets and SHR-1701 injection
.
Among them, SHR-1701 can promote the activation of effector T cells, and can also effectively improve the immune regulation in the tumor microenvironment, and ultimately effectively promote the immune system to kill tumor cells
.
SHR-1701 injection has carried out a number of solid tumor clinical trials in China and a phase I clinical trial in Australia
.
According to the industry, compared with the steady and declining proportion of next-generation biotherapy pipelines in major markets around the world, Chinese pharmaceutical companies have sprung up, showing strong innovative R&D capabilities
.
Data show that China's expenditure on cancer drugs has risen from US$640 million in 2016 to US$1.
36 billion in 2020, and the CAGR has reached 20.
8% in the past five years
.
According to the announcement issued by Hengrui Pharmaceuticals, up to now, Hengrui Pharmaceuticals has invested a total of about 402 million R&D expenses in related projects of apatinib mesylate; and has invested about R-1701 related research and development expenses in R-1701 related projects.
It is 238 million yuan, and the cumulative investment in the two products exceeds 640 million yuan
.
As pharmaceutical companies are in full swing in the research and development of new tumor drugs, various good news about anti-tumor drugs continues
.
For example, in addition to the aforementioned two anti-tumor drugs of Hengrui Pharmaceuticals, which have been approved for clinical trials, BeiGene also has good news recently, that is, on October 11, its Bruton’s tyrosine kinase (BTK) small Molecular inhibitor Baiyueze (Zebutinib) was successfully approved in Australia for the treatment of mantle cell lymphoma (MCL)
.
Lianhuan Pharmaceutical also issued an announcement stating that the company has recently received the "Drug Clinical Trial Approval Notice" for LH-1802 capsules (specification: 0.
1mg0.
5mg2mg) approved and issued by the National Medical Products Administration.
Carry out clinical trials
.
It is reported that LH-1802 is a class I anti-tumor innovative drug.
The proposed indication is hematoma or solid tumor.
The drug is a novel structure with independent intellectual property rights developed by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Lianhuan Pharmaceutical.
New small molecule anti-tumor drugs
.
In addition, most of the global multinational pharmaceutical companies have an oncology drug deployment in China, such as Roche, Sanofi, Novartis, Pfizer, and Eli Lilly.
Most companies have two or more oncology drug deployments
.
Nowadays, with the encouragement of national policies and the active contributions of major pharmaceutical companies, good news has repeatedly spread in the field of anti-tumor drugs, which has also brought more benefits to patients
.
However, some people pointed out that, from the perspective of the distribution of drug categories, China’s pharmaceutical market is still quite different from the global pharmaceutical market.
China is still dominated by traditional Chinese medicine, antimetabolites, plant alkaloids and other natural medicines.
The medicine share is small
.